Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2007-3-5
pubmed:abstractText
Olanzapine is a neuroleptic drug widely prescribed to treat schizophrenia and bipolar disorder. Although it is long known that modulation of the dopamine system is a basic mechanism of action of neuroleptics, their impact on reward functions mediated by dopamine is still poorly understood.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0033-3158
pubmed:author
pubmed:issnType
Print
pubmed:volume
191
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
823-33
pubmed:dateRevised
2008-11-21
pubmed:meshHeading
pubmed-meshheading:17265148-Antipsychotic Agents, pubmed-meshheading:17265148-Basal Ganglia, pubmed-meshheading:17265148-Benzodiazepines, pubmed-meshheading:17265148-Brain, pubmed-meshheading:17265148-Cerebrovascular Circulation, pubmed-meshheading:17265148-Cross-Over Studies, pubmed-meshheading:17265148-Dopamine, pubmed-meshheading:17265148-Double-Blind Method, pubmed-meshheading:17265148-Humans, pubmed-meshheading:17265148-Hypercapnia, pubmed-meshheading:17265148-Magnetic Resonance Imaging, pubmed-meshheading:17265148-Motivation, pubmed-meshheading:17265148-Oxygen, pubmed-meshheading:17265148-Oxygen Consumption, pubmed-meshheading:17265148-Pilot Projects, pubmed-meshheading:17265148-Prefrontal Cortex, pubmed-meshheading:17265148-Reaction Time, pubmed-meshheading:17265148-Reference Values, pubmed-meshheading:17265148-Reward, pubmed-meshheading:17265148-Serotonin Uptake Inhibitors
pubmed:year
2007
pubmed:articleTitle
Human reward system activation is modulated by a single dose of olanzapine in healthy subjects in an event-related, double-blind, placebo-controlled fMRI study.
pubmed:affiliation
Department of Psychiatry, University of Ulm, Leimgrubenweg 12-14, 89075, Ulm, Germany. birgit.abler@uni-ulm.de
pubmed:publicationType
Journal Article, Randomized Controlled Trial